Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B-Reference-Cited by-同舟云学术

Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

Published:2007-11 Issue:5 Volume:133 Page:1437-1444
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Gish Robert G.,Lok Anna S.,Chang Ting–Tsung,de Man Robert A.,Gadano Adrian,Sollano José,Han Kwang–Hyub,Chao You–Chen,Lee Shou–Dong,Harris Melissa,Yang Joanna,Colonno Richard,Brett–Smith Helena

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Viral hepatitis B;Lai;Lancet,2003

2. Management of hepatitis B: 2000—summary of a workshop;Lok;Gastroenterology,2001

3. Hepatitis B virus infection;Lee;N Engl J Med,1997

4. Hepatitis B virus infection—natural history and clinical consequences;Ganem;N Engl J Med,2004

5. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level;Chen;JAMA,2006

Cited by 314 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment;Frontiers in Cellular and Infection Microbiology;2024-08-07

2. Advances in the Pharmacological Management of Chronic Hepatitis B;American Journal of Therapeutics;2024-03-27

3. Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B;Journal of Viral Hepatitis;2024-01

4. Advances in the treatment of hepatogenous diabetes: A review;Medicine;2023-11-17

5. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment;Frontiers in Cellular and Infection Microbiology;2023-06-16